Neurotrophic keratitis/keratopathy (NK), a rare degenerative corneal disease, lacks effective pharmacologic therapies.1 Because NK pathology involves trigeminal nerve damage and loss of corneal innervation, nerve growth factor (NGF) is surmised to promote healing of NK.2 Preliminary studies with murine NGF demonstrated efficacy for treating corneal neurotrophic ulcers;3 however, the complex tertiary structure of NGF has complicated the production of recombinant human NGF (rhNGF) suitable for clinical development. To this end, we developed an Escherichia coli–derived rhNGF formulation that demonstrated to be well tolerated and safe for topical ophthalmic use in a phase I study in healthy volunteers.4 We report phase I results of topical rhNGF for patients with moderate-to-severe NK.
Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis / Bonini, Stefano; Lambiase, Alessandro; Rama, Paolo; Filatori, Isabella; Allegretti, Marcello; Chao, Wendy; Mantelli, Flavio; Bonini, Stefano; Lambiase, Alessandro; Rama, Paolo; Messmer, Elisabeth; Aragona, Pasquale; Geerling, Gerd; Mastropasqua, Leonardo; Mencucci, Rita; Dart, John; Leonardi, Andrea; Montero, Jesus; Rolando, Maurizio; Reinhard, Thomas; Cursiefen, Claus; Etxebarria, Jaime; Gabison, Eric; Szaflik, Jacek P.; Bouheraoua, Nacim; De La Paz, Maria; Sainz de la Maza, Maite; Wylegala, Edward; Figueiredo, Francisco; Fogagnolo, Paolo; Hossain, Parwez; Lorenz, Katrin; Robert, Pierre-Yves; Benitez del Castillo, José; Creuzot-Garcher, Catherine; Kruse, Friedrich; Malecaze, François; Merayo-Lloves, Jesús; Rauz, Saaeha; Alio, Jorge; Carley, Fiona; Kanna, Ramaesh; Koppen, Carina; Nemeth, Janos; Murta, Joaquim Neto; Torrao, Luis. - In: OPHTHALMOLOGY. - ISSN 0161-6420. - STAMPA. - (2018). [10.1016/j.ophtha.2018.03.004]
Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis
Lambiase, Alessandro
;LEONARDI, ANDREA;
2018
Abstract
Neurotrophic keratitis/keratopathy (NK), a rare degenerative corneal disease, lacks effective pharmacologic therapies.1 Because NK pathology involves trigeminal nerve damage and loss of corneal innervation, nerve growth factor (NGF) is surmised to promote healing of NK.2 Preliminary studies with murine NGF demonstrated efficacy for treating corneal neurotrophic ulcers;3 however, the complex tertiary structure of NGF has complicated the production of recombinant human NGF (rhNGF) suitable for clinical development. To this end, we developed an Escherichia coli–derived rhNGF formulation that demonstrated to be well tolerated and safe for topical ophthalmic use in a phase I study in healthy volunteers.4 We report phase I results of topical rhNGF for patients with moderate-to-severe NK.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bonini_Phase I trial_2018.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
182.23 kB
Formato
Adobe PDF
|
182.23 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
